within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M04A_AntigoutPreparations.M04AA03_Febuxostat;

model Febuxostat
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.49,
    Cl = 2.722222222222223e-06,
    adminDuration = 600,
    adminMass = 80 / 1000000,
    adminCount = 1,
    Vd = 0.029,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.011183333333333333,
    Tlag = 15.0,
    Vdp = 0.0381,
    k12 = 5.500000000000001e-06,
    k21 = 5.500000000000001e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Febuxostat</td></tr><tr><td>ATC code:</td><td>M04AA03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>80</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>29.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>9.8</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Febuxostat is a non-purine selective inhibitor of xanthine oxidase, used primarily for the treatment of chronic hyperuricemia in patients with gout. It is an orally administered medication approved in many countries, though its use may be restricted in some regions due to cardiovascular concerns.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Liu, XX, et al., &amp; Wang, SL (2012). Pharmacokinetics of febuxostat in healthy Chinese volunteers. <i>Arzneimittel-Forschung</i> 62(10) 463–469. DOI:<a href=\"https://doi.org/10.1055/s-0032-1321847\">10.1055/s-0032-1321847</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22956350/\">https://pubmed.ncbi.nlm.nih.gov/22956350</a></p></li><li><p>Lin, M, et al., &amp; Wu, L (2017). Effects of UDP-glucuronosyltransferase (UGT) polymorphisms on the pharmacokinetics of febuxostat in healthy Chinese volunteers. <i>Drug metabolism and pharmacokinetics</i> 32(1) 77–84. DOI:<a href=\"https://doi.org/10.1016/j.dmpk.2016.08.003\">10.1016/j.dmpk.2016.08.003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28131654/\">https://pubmed.ncbi.nlm.nih.gov/28131654</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M04AA03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Febuxostat;
